Lombard Odier Asset Management (Switzerland)’s Vertex Pharmaceuticals VRTX Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.51M	Sell	9,072 -240	-3%	-$106K	0.14%	138
2026 Q1	$4.16M	Sell	9,312 -2,380	-20%	-$1.11M	0.16%	139
2025 Q4	$5.3M	Buy	+11,692	New	+$5.04M	0.23%	97
2024 Q2	–	Sell	-34,007	Closed	-$14.2M	–	351
2024 Q1	$14.2M	Sell	34,007 -2,120	-6%	-$896K	1%	17
2023 Q4	$14.7M	Sell	36,127 -16,729	-32%	-$6.18M	1.97%	12
2023 Q3	$18.4M	Sell	52,856 -4,988	-9%	-$1.74M	2.97%	4
2023 Q2	$20.4M	Buy	57,844 +10,359	+22%	+$3.49M	2.89%	7
2023 Q1	$15M	Buy	47,485 +44,951	+1,774%	+$13.5M	1.31%	23
2022 Q4	$732K	Buy	2,534 +1,192	+89%	+$363K	0.06%	217
2022 Q3	$389K	Sell	1,342 -1,352	-50%	-$389K	0.03%	209
2022 Q2	$759K	Buy	+2,694	New	+$721K	0.06%	176
2022 Q1	–	Sell	-2,229	Closed	-$489K	–	390
2021 Q4	$489K	Buy	+2,229	New	+$433K	0.03%	242
2021 Q3	–	Sell	-1,395	Closed	-$281K	–	472
2021 Q2	$281K	Sell	1,395 -267	-16%	-$55.8K	0.01%	439
2021 Q1	$357K	Buy	+1,662	New	+$365K	0.02%	290
2020 Q4	–	Sell	-978	Closed	-$266K	–	349
2020 Q3	$266K	Buy	+978	New	+$270K	0.03%	319
2020 Q2	–	Sell	-1,058	Closed	-$252K	–	330
2020 Q1	$252K	Hold	1,058	–	–	0.03%	305
2019 Q4	$232K	Buy	+1,058	New	+$214K	0.02%	340
2016 Q2	–	Sell	-1,543	Closed	-$123K	–	431
2016 Q1	$123K	Hold	1,543	–	–	0.01%	321
2015 Q4	$196K	Buy	+1,543	New	+$186K	0.02%	267
2015 Q3	–	Sell	-1,683	Closed	-$208K	–	410
2015 Q2	$208K	Sell	1,683 -897	-35%	-$113K	0.02%	412
2015 Q1	$305K	Buy	2,580 +804	+45%	+$96.3K	0.03%	323
2014 Q4	$212K	Sell	1,776 -22,142	-93%	-$2.49M	0.02%	383
2014 Q3	$2.7M	Buy	23,918 +21,358	+834%	+$2.03M	0.07%	299
2014 Q2	$241K	Buy	+2,560	New	+$180K	0.03%	340

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s VRTX Position: Q2 2026 in Review

Lombard Odier Asset Management (Switzerland) reduced its Vertex Pharmaceuticals (VRTX) stake by 2.6% in Q2 2026, selling an estimated $106K and leaving 9,072 shares worth $4.51M. The position accounts for 0.14% of the portfolio, ranked #138.

Lombard Odier Asset Management (Switzerland) first reported a position in VRTX in Q2 2014 and has held it in 24 quarters since. The position peaked at $20.4M in Q2 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Lombard Odier Asset Management (Switzerland) held 9,072 shares of Vertex Pharmaceuticals worth $4.51M as of Q2 2026.
Lombard Odier Asset Management (Switzerland) sold 240 Vertex Pharmaceuticals shares in Q2 2026, an estimated $106K.
Vertex Pharmaceuticals made up 0.14% of Lombard Odier Asset Management (Switzerland)'s portfolio in Q2 2026, its #138 holding.
Lombard Odier Asset Management (Switzerland) first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 24 quarters since.
Lombard Odier Asset Management (Switzerland)'s Vertex Pharmaceuticals position peaked at $20.4M in Q2 2023.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2026, filed 14 Aug 2026.